BRC
MYGN icon

Blue Ridge Capital’s Myriad Genetics MYGN Stock Holding History

Blue Ridge Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,000,000
Closed -$34.2M – 54
2014
Q1 		$34.2M Buy
+1,000,000
New +$31M 0.38% 43

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Blue Ridge Capital's MYGN Position: Q2 2014 in Review

Blue Ridge Capital sold out of Myriad Genetics (MYGN) in Q2 2014, closing a stake of 1,000,000 shares — an estimated $34.2M sold.

Blue Ridge Capital first reported a position in MYGN in Q1 2014 and held it in 1 quarter. The position peaked at $34.2M in Q1 2014. 283 funds tracked by Wall St. Rank hold MYGN as of Q2 2014.

  • Blue Ridge Capital reported no remaining Myriad Genetics position as of Q2 2014 after selling out during the quarter.
  • Blue Ridge Capital sold 1,000,000 Myriad Genetics shares in Q2 2014, an estimated $34.2M.
  • Blue Ridge Capital first reported a position in Myriad Genetics in Q1 2014 and held it in 1 quarter.
  • Blue Ridge Capital's Myriad Genetics position peaked at $34.2M in Q1 2014.
  • 283 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2014.

Based on Blue Ridge Capital's 13F filing for Q2 2014, filed 14 Aug 2014.